Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Neoplasms | 115 | 2022 | 621 | 14.360 |
Why?
|
Carcinoma, Renal Cell | 104 | 2022 | 426 | 13.680 |
Why?
|
Antineoplastic Agents | 91 | 2021 | 2360 | 5.810 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 69 | 2021 | 2438 | 4.940 |
Why?
|
Urinary Bladder Neoplasms | 40 | 2024 | 383 | 4.340 |
Why?
|
Prostatic Neoplasms | 62 | 2023 | 1721 | 3.930 |
Why?
|
Angiogenesis Inhibitors | 24 | 2022 | 311 | 3.800 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 15 | 2022 | 111 | 3.390 |
Why?
|
Carcinoma, Transitional Cell | 24 | 2019 | 164 | 3.240 |
Why?
|
Protein Kinase Inhibitors | 22 | 2022 | 589 | 2.810 |
Why?
|
Deoxycytidine | 27 | 2021 | 237 | 2.700 |
Why?
|
Urologic Neoplasms | 15 | 2021 | 77 | 2.520 |
Why?
|
Neoplasm Metastasis | 52 | 2021 | 1056 | 2.420 |
Why?
|
Neoplasms | 27 | 2023 | 2898 | 2.090 |
Why?
|
Pyrroles | 15 | 2021 | 184 | 2.080 |
Why?
|
Pyridines | 18 | 2019 | 310 | 2.060 |
Why?
|
Indoles | 15 | 2016 | 318 | 2.060 |
Why?
|
Benzenesulfonates | 16 | 2012 | 66 | 2.040 |
Why?
|
Molecular Targeted Therapy | 9 | 2023 | 266 | 1.950 |
Why?
|
Humans | 315 | 2024 | 86643 | 1.860 |
Why?
|
Aged | 168 | 2024 | 18415 | 1.860 |
Why?
|
Niacinamide | 20 | 2016 | 116 | 1.800 |
Why?
|
Phenylurea Compounds | 20 | 2016 | 114 | 1.770 |
Why?
|
Male | 220 | 2023 | 40965 | 1.750 |
Why?
|
Middle Aged | 171 | 2022 | 25028 | 1.630 |
Why?
|
Clinical Trials, Phase II as Topic | 16 | 2016 | 176 | 1.630 |
Why?
|
Aged, 80 and over | 88 | 2022 | 6509 | 1.540 |
Why?
|
Neovascularization, Pathologic | 10 | 2021 | 353 | 1.500 |
Why?
|
Treatment Outcome | 90 | 2023 | 7993 | 1.450 |
Why?
|
Cisplatin | 21 | 2024 | 612 | 1.440 |
Why?
|
Sirolimus | 8 | 2020 | 169 | 1.390 |
Why?
|
Androgen Antagonists | 17 | 2022 | 144 | 1.360 |
Why?
|
Magnetic Resonance Imaging | 11 | 2016 | 3362 | 1.350 |
Why?
|
Quinazolines | 9 | 2016 | 220 | 1.280 |
Why?
|
Randomized Controlled Trials as Topic | 13 | 2016 | 865 | 1.280 |
Why?
|
Research Design | 14 | 2016 | 594 | 1.260 |
Why?
|
Disease-Free Survival | 46 | 2021 | 1204 | 1.260 |
Why?
|
Testosterone | 4 | 2018 | 271 | 1.240 |
Why?
|
Contrast Media | 10 | 2016 | 1078 | 1.240 |
Why?
|
Interferon-alpha | 12 | 2015 | 233 | 1.150 |
Why?
|
Biomarkers, Tumor | 23 | 2022 | 1464 | 1.150 |
Why?
|
Pyrimidines | 7 | 2022 | 370 | 1.110 |
Why?
|
Gadolinium DTPA | 8 | 2013 | 261 | 1.110 |
Why?
|
Survival Analysis | 39 | 2021 | 1538 | 1.090 |
Why?
|
Clinical Trials as Topic | 18 | 2016 | 1169 | 1.060 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2021 | 1313 | 1.040 |
Why?
|
Female | 140 | 2022 | 44532 | 1.020 |
Why?
|
Antibodies, Monoclonal | 20 | 2019 | 1376 | 1.010 |
Why?
|
Adenocarcinoma | 17 | 2023 | 1169 | 0.990 |
Why?
|
Disease Progression | 32 | 2021 | 1531 | 0.980 |
Why?
|
Bevacizumab | 21 | 2021 | 281 | 0.970 |
Why?
|
Antineoplastic Agents, Hormonal | 12 | 2014 | 150 | 0.970 |
Why?
|
Prostate-Specific Antigen | 24 | 2022 | 353 | 0.960 |
Why?
|
Neoplasm Staging | 28 | 2019 | 1939 | 0.940 |
Why?
|
Pharmacogenetics | 6 | 2019 | 434 | 0.920 |
Why?
|
Sulfonamides | 3 | 2016 | 300 | 0.910 |
Why?
|
Adult | 103 | 2021 | 25648 | 0.900 |
Why?
|
Antimetabolites, Antineoplastic | 10 | 2007 | 236 | 0.890 |
Why?
|
Interleukin-2 | 11 | 2008 | 249 | 0.860 |
Why?
|
Fluorouracil | 10 | 2011 | 556 | 0.850 |
Why?
|
Drug Administration Schedule | 30 | 2020 | 916 | 0.830 |
Why?
|
Antibodies, Monoclonal, Humanized | 25 | 2021 | 930 | 0.780 |
Why?
|
Health Expenditures | 1 | 2021 | 86 | 0.760 |
Why?
|
Health Literacy | 1 | 2021 | 70 | 0.750 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 7 | 2023 | 70 | 0.750 |
Why?
|
Vascular Endothelial Growth Factor A | 17 | 2023 | 407 | 0.750 |
Why?
|
Imidazoles | 8 | 2016 | 162 | 0.730 |
Why?
|
Societies, Scientific | 1 | 2020 | 44 | 0.720 |
Why?
|
Conflict of Interest | 1 | 2020 | 67 | 0.720 |
Why?
|
Vinblastine | 8 | 2015 | 108 | 0.690 |
Why?
|
Androstenes | 6 | 2021 | 43 | 0.680 |
Why?
|
Urothelium | 9 | 2016 | 70 | 0.680 |
Why?
|
Prognosis | 29 | 2018 | 3679 | 0.670 |
Why?
|
Quinolines | 5 | 2020 | 95 | 0.660 |
Why?
|
Infusions, Intravenous | 19 | 2010 | 429 | 0.650 |
Why?
|
Indazoles | 7 | 2021 | 68 | 0.640 |
Why?
|
Survival Rate | 25 | 2020 | 1863 | 0.640 |
Why?
|
Benzodioxoles | 2 | 2015 | 16 | 0.630 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2009 | 114 | 0.620 |
Why?
|
Drug Design | 4 | 2007 | 124 | 0.620 |
Why?
|
Doxorubicin | 9 | 2019 | 295 | 0.610 |
Why?
|
Drug Resistance, Neoplasm | 15 | 2020 | 592 | 0.590 |
Why?
|
Carcinoma | 5 | 2012 | 436 | 0.580 |
Why?
|
Prospective Studies | 23 | 2023 | 4213 | 0.580 |
Why?
|
Castration | 4 | 2012 | 41 | 0.570 |
Why?
|
Bone Neoplasms | 9 | 2016 | 322 | 0.570 |
Why?
|
Methotrexate | 8 | 2015 | 249 | 0.570 |
Why?
|
Carcinoma, Papillary | 4 | 2017 | 158 | 0.560 |
Why?
|
Chromosomes, Human, Pair 9 | 6 | 2001 | 86 | 0.550 |
Why?
|
Patient Selection | 10 | 2023 | 685 | 0.550 |
Why?
|
Orchiectomy | 10 | 2016 | 68 | 0.540 |
Why?
|
Double-Blind Method | 18 | 2022 | 1823 | 0.530 |
Why?
|
Immunotherapy | 8 | 2022 | 629 | 0.510 |
Why?
|
Image Enhancement | 2 | 2009 | 563 | 0.500 |
Why?
|
Neoplasms, Hormone-Dependent | 5 | 2011 | 40 | 0.490 |
Why?
|
Pteridines | 1 | 2013 | 5 | 0.490 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2013 | 663 | 0.490 |
Why?
|
Nomograms | 2 | 2014 | 28 | 0.480 |
Why?
|
Organoplatinum Compounds | 2 | 2005 | 94 | 0.480 |
Why?
|
Administration, Oral | 15 | 2020 | 684 | 0.470 |
Why?
|
Quality of Life | 9 | 2021 | 1585 | 0.470 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2016 | 172 | 0.460 |
Why?
|
Prostatectomy | 6 | 2012 | 471 | 0.450 |
Why?
|
Academic Medical Centers | 1 | 2015 | 379 | 0.440 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 6 | 2014 | 81 | 0.440 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2011 | 381 | 0.440 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 138 | 0.430 |
Why?
|
Lymphatic Metastasis | 7 | 2018 | 486 | 0.420 |
Why?
|
Benzamides | 3 | 2022 | 229 | 0.410 |
Why?
|
Subtraction Technique | 2 | 2009 | 133 | 0.400 |
Why?
|
Benzimidazoles | 4 | 2017 | 140 | 0.400 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 329 | 0.400 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2016 | 468 | 0.390 |
Why?
|
Anilides | 4 | 2019 | 47 | 0.390 |
Why?
|
Flavonoids | 3 | 2000 | 85 | 0.390 |
Why?
|
Gene Expression Profiling | 10 | 2018 | 1384 | 0.380 |
Why?
|
Everolimus | 4 | 2016 | 40 | 0.380 |
Why?
|
Combined Modality Therapy | 16 | 2024 | 1686 | 0.380 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2018 | 1961 | 0.380 |
Why?
|
Forecasting | 2 | 2009 | 304 | 0.380 |
Why?
|
Signal Transduction | 11 | 2019 | 3241 | 0.370 |
Why?
|
Liver Neoplasms | 9 | 2021 | 736 | 0.370 |
Why?
|
Models, Biological | 6 | 2013 | 1749 | 0.370 |
Why?
|
Depsipeptides | 2 | 2009 | 29 | 0.370 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2015 | 138 | 0.370 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2021 | 182 | 0.370 |
Why?
|
Neoplasm Invasiveness | 9 | 2024 | 552 | 0.360 |
Why?
|
Follow-Up Studies | 16 | 2020 | 3640 | 0.360 |
Why?
|
Capecitabine | 5 | 2024 | 96 | 0.360 |
Why?
|
Genes, Tumor Suppressor | 9 | 2004 | 157 | 0.360 |
Why?
|
Cetuximab | 2 | 2020 | 113 | 0.360 |
Why?
|
Piperidines | 3 | 2000 | 181 | 0.360 |
Why?
|
Salvage Therapy | 5 | 2012 | 233 | 0.350 |
Why?
|
Pyrrolidinones | 2 | 2020 | 16 | 0.350 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2009 | 8 | 0.350 |
Why?
|
Prostatic Hyperplasia | 1 | 2010 | 88 | 0.350 |
Why?
|
Colorectal Neoplasms | 4 | 2012 | 938 | 0.340 |
Why?
|
Germ-Line Mutation | 3 | 2023 | 329 | 0.340 |
Why?
|
Antigens, Surface | 1 | 2009 | 101 | 0.340 |
Why?
|
Antineoplastic Agents, Immunological | 3 | 2020 | 185 | 0.340 |
Why?
|
Pyrazines | 3 | 2006 | 92 | 0.340 |
Why?
|
Naphthalenes | 3 | 2014 | 45 | 0.340 |
Why?
|
Precision Medicine | 5 | 2023 | 395 | 0.330 |
Why?
|
Drug Prescriptions | 3 | 2019 | 141 | 0.330 |
Why?
|
Risk Assessment | 9 | 2016 | 2261 | 0.330 |
Why?
|
Cell Cycle Proteins | 4 | 2009 | 388 | 0.330 |
Why?
|
Cystectomy | 4 | 2024 | 102 | 0.330 |
Why?
|
Androgens | 2 | 2009 | 167 | 0.320 |
Why?
|
Venous Thrombosis | 2 | 2019 | 243 | 0.320 |
Why?
|
Kaplan-Meier Estimate | 14 | 2018 | 860 | 0.310 |
Why?
|
Boronic Acids | 2 | 2006 | 55 | 0.310 |
Why?
|
Chicago | 7 | 2017 | 1379 | 0.300 |
Why?
|
Epothilones | 1 | 2007 | 13 | 0.300 |
Why?
|
Clinical Decision-Making | 3 | 2019 | 257 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 189 | 0.300 |
Why?
|
Urogenital Neoplasms | 2 | 2006 | 23 | 0.300 |
Why?
|
Tubulin Modulators | 1 | 2007 | 24 | 0.300 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 178 | 0.300 |
Why?
|
Chromosomes, Human | 1 | 2007 | 66 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2009 | 460 | 0.290 |
Why?
|
Tumor Suppressor Proteins | 2 | 2001 | 279 | 0.290 |
Why?
|
Anxiety | 1 | 2009 | 287 | 0.290 |
Why?
|
Genes, p16 | 3 | 2001 | 11 | 0.290 |
Why?
|
Apoptosis | 6 | 2005 | 1683 | 0.290 |
Why?
|
Photosensitivity Disorders | 1 | 2006 | 15 | 0.290 |
Why?
|
Keratosis | 1 | 2006 | 21 | 0.290 |
Why?
|
Growth Inhibitors | 1 | 2006 | 41 | 0.290 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 151 | 0.280 |
Why?
|
Cognition | 2 | 2010 | 570 | 0.280 |
Why?
|
Cancer Vaccines | 3 | 2016 | 156 | 0.280 |
Why?
|
Floxuridine | 2 | 2004 | 11 | 0.280 |
Why?
|
Cell Hypoxia | 1 | 2007 | 164 | 0.280 |
Why?
|
Drug Eruptions | 1 | 2006 | 35 | 0.280 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2005 | 19 | 0.280 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 4 | 2013 | 101 | 0.280 |
Why?
|
Time Factors | 17 | 2016 | 5210 | 0.270 |
Why?
|
Urinary Bladder | 3 | 2024 | 246 | 0.270 |
Why?
|
Neoplasm Proteins | 2 | 2007 | 532 | 0.270 |
Why?
|
Thalidomide | 2 | 2002 | 54 | 0.270 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2002 | 112 | 0.270 |
Why?
|
Chromosome Aberrations | 4 | 2006 | 387 | 0.270 |
Why?
|
Proportional Hazards Models | 9 | 2016 | 859 | 0.260 |
Why?
|
Enzyme Inhibitors | 5 | 2009 | 639 | 0.260 |
Why?
|
Ureteral Neoplasms | 1 | 2004 | 13 | 0.250 |
Why?
|
Triazoles | 1 | 2005 | 96 | 0.250 |
Why?
|
Head and Neck Neoplasms | 3 | 2020 | 1052 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2018 | 1197 | 0.250 |
Why?
|
Chromosome Deletion | 5 | 2001 | 229 | 0.250 |
Why?
|
Endpoint Determination | 5 | 2013 | 60 | 0.250 |
Why?
|
Rare Diseases | 1 | 2004 | 59 | 0.250 |
Why?
|
Interferon-gamma | 3 | 2016 | 444 | 0.250 |
Why?
|
Cell Division | 4 | 2003 | 696 | 0.250 |
Why?
|
Ipilimumab | 2 | 2022 | 58 | 0.240 |
Why?
|
Mutation | 10 | 2021 | 3968 | 0.240 |
Why?
|
Ambulatory Care | 2 | 2013 | 181 | 0.240 |
Why?
|
Pancreatic Neoplasms | 4 | 2015 | 645 | 0.240 |
Why?
|
Receptors, Androgen | 4 | 2017 | 113 | 0.240 |
Why?
|
Protease Inhibitors | 1 | 2004 | 72 | 0.240 |
Why?
|
Nuclear Medicine | 1 | 2023 | 12 | 0.230 |
Why?
|
Abducens Nerve Diseases | 1 | 2003 | 3 | 0.230 |
Why?
|
Biomarkers | 7 | 2022 | 1718 | 0.230 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2014 | 70 | 0.230 |
Why?
|
Paralysis | 1 | 2003 | 23 | 0.230 |
Why?
|
Rituximab | 3 | 2021 | 116 | 0.230 |
Why?
|
Taxoids | 6 | 2013 | 129 | 0.230 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 7 | 2006 | 104 | 0.220 |
Why?
|
Genomics | 3 | 2021 | 720 | 0.220 |
Why?
|
Accreditation | 1 | 2013 | 60 | 0.220 |
Why?
|
Nuclear Proteins | 4 | 2000 | 696 | 0.220 |
Why?
|
Pharmacogenomic Testing | 3 | 2019 | 97 | 0.220 |
Why?
|
Mesothelioma | 3 | 2012 | 311 | 0.220 |
Why?
|
Immunoenzyme Techniques | 3 | 2011 | 303 | 0.220 |
Why?
|
Treatment Failure | 7 | 2011 | 285 | 0.220 |
Why?
|
Prescription Drugs | 2 | 2021 | 36 | 0.210 |
Why?
|
Homozygote | 3 | 2001 | 200 | 0.210 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 30 | 0.210 |
Why?
|
Maximum Tolerated Dose | 8 | 2019 | 270 | 0.210 |
Why?
|
Isotretinoin | 2 | 2000 | 23 | 0.210 |
Why?
|
Neoadjuvant Therapy | 5 | 2019 | 318 | 0.210 |
Why?
|
Guidelines as Topic | 2 | 2020 | 162 | 0.210 |
Why?
|
Quinolones | 4 | 2014 | 60 | 0.210 |
Why?
|
Meningeal Neoplasms | 1 | 2022 | 61 | 0.210 |
Why?
|
Chromosome Disorders | 2 | 2001 | 114 | 0.210 |
Why?
|
Dacarbazine | 1 | 2002 | 102 | 0.210 |
Why?
|
Knowledge | 1 | 2021 | 29 | 0.210 |
Why?
|
Meningioma | 1 | 2022 | 60 | 0.210 |
Why?
|
Thromboembolism | 1 | 2002 | 119 | 0.210 |
Why?
|
Gene Deletion | 3 | 2001 | 329 | 0.200 |
Why?
|
Paclitaxel | 5 | 2009 | 460 | 0.200 |
Why?
|
Muscle Neoplasms | 1 | 2001 | 18 | 0.200 |
Why?
|
Faculty, Medical | 1 | 2013 | 178 | 0.200 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2001 | 348 | 0.200 |
Why?
|
Diphosphonates | 2 | 2014 | 36 | 0.200 |
Why?
|
Metaphase | 1 | 2000 | 25 | 0.190 |
Why?
|
Retrospective Studies | 14 | 2021 | 8489 | 0.190 |
Why?
|
Cell Transformation, Viral | 2 | 2000 | 40 | 0.190 |
Why?
|
G2 Phase | 1 | 2000 | 34 | 0.190 |
Why?
|
Bone Density Conservation Agents | 2 | 2014 | 45 | 0.190 |
Why?
|
Prednisone | 6 | 2019 | 258 | 0.190 |
Why?
|
Models, Statistical | 2 | 2015 | 574 | 0.180 |
Why?
|
Dietary Supplements | 1 | 2021 | 128 | 0.180 |
Why?
|
Tumor Cells, Cultured | 10 | 1999 | 1041 | 0.180 |
Why?
|
Peritoneal Neoplasms | 3 | 2012 | 177 | 0.180 |
Why?
|
Interleukin-6 | 2 | 2009 | 256 | 0.180 |
Why?
|
Hydrogen Peroxide | 1 | 2000 | 158 | 0.180 |
Why?
|
Tumor Burden | 3 | 2013 | 289 | 0.180 |
Why?
|
Point-of-Care Systems | 2 | 2019 | 141 | 0.180 |
Why?
|
Suramin | 3 | 2004 | 27 | 0.180 |
Why?
|
Injections, Subcutaneous | 5 | 2008 | 117 | 0.180 |
Why?
|
Pulmonary Embolism | 1 | 2002 | 222 | 0.180 |
Why?
|
Sesquiterpenes | 1 | 1999 | 13 | 0.180 |
Why?
|
Receptor, EphB4 | 1 | 2019 | 24 | 0.180 |
Why?
|
Decision Support Systems, Clinical | 2 | 2017 | 103 | 0.180 |
Why?
|
Cell Cycle | 2 | 1999 | 502 | 0.180 |
Why?
|
Papillomaviridae | 2 | 2000 | 153 | 0.180 |
Why?
|
Algorithms | 1 | 2007 | 1830 | 0.180 |
Why?
|
Internal Medicine | 1 | 2013 | 347 | 0.170 |
Why?
|
Kidney Pelvis | 2 | 2018 | 50 | 0.170 |
Why?
|
Radiosurgery | 2 | 2013 | 272 | 0.170 |
Why?
|
Venae Cavae | 1 | 2019 | 14 | 0.170 |
Why?
|
Reproducibility of Results | 4 | 2011 | 2705 | 0.170 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2019 | 83 | 0.170 |
Why?
|
Education, Medical, Graduate | 1 | 2013 | 369 | 0.170 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2009 | 85 | 0.170 |
Why?
|
Drug Resistance, Multiple | 1 | 1999 | 20 | 0.170 |
Why?
|
Cohort Studies | 6 | 2017 | 2767 | 0.170 |
Why?
|
Photochemotherapy | 1 | 1999 | 97 | 0.170 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 166 | 0.170 |
Why?
|
Early Termination of Clinical Trials | 3 | 2013 | 20 | 0.170 |
Why?
|
Fatigue | 7 | 2013 | 174 | 0.170 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2011 | 294 | 0.170 |
Why?
|
Clinical Protocols | 1 | 2019 | 156 | 0.170 |
Why?
|
Immunohistochemistry | 9 | 2014 | 1753 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2023 | 408 | 0.160 |
Why?
|
T-Lymphocytes | 4 | 2016 | 1195 | 0.160 |
Why?
|
Protein Kinase C | 1 | 1999 | 270 | 0.160 |
Why?
|
Genes, bcl-2 | 1 | 1998 | 16 | 0.160 |
Why?
|
Lipocalin-2 | 1 | 2018 | 38 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2016 | 23 | 0.160 |
Why?
|
Cystatin C | 1 | 2018 | 31 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 120 | 0.160 |
Why?
|
Carrier Proteins | 3 | 1996 | 673 | 0.160 |
Why?
|
Chromosome Mapping | 5 | 2006 | 1074 | 0.160 |
Why?
|
MAP Kinase Kinase 4 | 3 | 2005 | 67 | 0.160 |
Why?
|
Lung Neoplasms | 8 | 2013 | 2262 | 0.160 |
Why?
|
Placebos | 4 | 2012 | 218 | 0.160 |
Why?
|
Recombinant Proteins | 4 | 2009 | 1014 | 0.150 |
Why?
|
Food | 1 | 2018 | 86 | 0.150 |
Why?
|
Clinical Competence | 1 | 2013 | 751 | 0.150 |
Why?
|
United States | 11 | 2018 | 6672 | 0.150 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2008 | 103 | 0.150 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
Perioperative Care | 1 | 2019 | 161 | 0.150 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 57 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 199 | 0.140 |
Why?
|
Disease Management | 3 | 2019 | 327 | 0.140 |
Why?
|
Kallikreins | 2 | 2016 | 47 | 0.140 |
Why?
|
Oncogene Proteins, Viral | 1 | 1996 | 34 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2016 | 55 | 0.140 |
Why?
|
Receptor, ErbB-3 | 1 | 2016 | 18 | 0.140 |
Why?
|
Diagnostic Imaging | 3 | 2016 | 469 | 0.140 |
Why?
|
Surveys and Questionnaires | 6 | 2021 | 2501 | 0.140 |
Why?
|
Medical Oncology | 2 | 2012 | 359 | 0.140 |
Why?
|
Safety | 4 | 2010 | 152 | 0.140 |
Why?
|
Tumor Microenvironment | 2 | 2016 | 418 | 0.140 |
Why?
|
Sensitivity and Specificity | 4 | 2009 | 1991 | 0.140 |
Why?
|
Radiography | 3 | 2014 | 813 | 0.140 |
Why?
|
Melanoma | 3 | 2004 | 459 | 0.140 |
Why?
|
Organometallic Compounds | 1 | 2016 | 132 | 0.140 |
Why?
|
Animals | 16 | 2023 | 26582 | 0.130 |
Why?
|
DNA Repair | 1 | 2017 | 356 | 0.130 |
Why?
|
Drug Approval | 1 | 2016 | 62 | 0.130 |
Why?
|
Membrane Proteins | 1 | 2002 | 1196 | 0.130 |
Why?
|
Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 1 | 2015 | 44 | 0.130 |
Why?
|
Mice | 10 | 2023 | 11352 | 0.130 |
Why?
|
Kidney | 2 | 2016 | 1241 | 0.130 |
Why?
|
Interleukin-4 | 1 | 1995 | 127 | 0.130 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 93 | 0.130 |
Why?
|
Physician-Patient Relations | 2 | 2019 | 610 | 0.130 |
Why?
|
Pelvic Neoplasms | 1 | 2015 | 45 | 0.130 |
Why?
|
Diarrhea | 4 | 2011 | 182 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2015 | 106 | 0.130 |
Why?
|
Sample Size | 3 | 2013 | 130 | 0.130 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 103 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2013 | 763 | 0.130 |
Why?
|
Immunologic Factors | 1 | 2016 | 170 | 0.130 |
Why?
|
Mitotane | 1 | 2014 | 2 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 3 | 2005 | 196 | 0.130 |
Why?
|
Cellular Senescence | 4 | 2000 | 94 | 0.130 |
Why?
|
Receptor, ErbB-2 | 1 | 2016 | 223 | 0.120 |
Why?
|
Clinical Trials, Phase I as Topic | 4 | 2012 | 155 | 0.120 |
Why?
|
Genetic Markers | 2 | 2011 | 476 | 0.120 |
Why?
|
Adrenocortical Carcinoma | 1 | 2014 | 12 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 2 | 2010 | 557 | 0.120 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2014 | 18 | 0.120 |
Why?
|
Imidazolidines | 2 | 2005 | 5 | 0.120 |
Why?
|
Acute Kidney Injury | 1 | 2018 | 295 | 0.120 |
Why?
|
Folic Acid Antagonists | 2 | 2008 | 19 | 0.120 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2014 | 18 | 0.120 |
Why?
|
Universities | 3 | 2011 | 135 | 0.120 |
Why?
|
Genome, Human | 1 | 2019 | 756 | 0.120 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 199 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2019 | 894 | 0.120 |
Why?
|
Computer Simulation | 2 | 2009 | 1078 | 0.120 |
Why?
|
Internship and Residency | 1 | 2013 | 1004 | 0.120 |
Why?
|
Sulindac | 2 | 2005 | 10 | 0.120 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 220 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 3 | 2002 | 276 | 0.120 |
Why?
|
Confidence Intervals | 5 | 2016 | 229 | 0.120 |
Why?
|
Lymph Node Excision | 1 | 2015 | 217 | 0.120 |
Why?
|
Sarcoma | 1 | 2015 | 215 | 0.110 |
Why?
|
Repressor Proteins | 1 | 1996 | 403 | 0.110 |
Why?
|
Transplantation, Heterologous | 2 | 2012 | 363 | 0.110 |
Why?
|
Bone and Bones | 1 | 2014 | 265 | 0.110 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2007 | 302 | 0.110 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2013 | 36 | 0.110 |
Why?
|
src-Family Kinases | 2 | 2011 | 74 | 0.110 |
Why?
|
Longitudinal Studies | 2 | 2020 | 1019 | 0.110 |
Why?
|
Up-Regulation | 3 | 2016 | 712 | 0.110 |
Why?
|
Probability | 3 | 2009 | 355 | 0.110 |
Why?
|
Feasibility Studies | 5 | 2019 | 751 | 0.110 |
Why?
|
Pilot Projects | 3 | 2010 | 839 | 0.110 |
Why?
|
Prostatic Intraepithelial Neoplasia | 2 | 2008 | 21 | 0.100 |
Why?
|
Accidental Falls | 2 | 2011 | 50 | 0.100 |
Why?
|
ROC Curve | 3 | 2010 | 752 | 0.100 |
Why?
|
Lactams, Macrocyclic | 1 | 2011 | 14 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2019 | 153 | 0.100 |
Why?
|
Benzoquinones | 1 | 2011 | 27 | 0.100 |
Why?
|
Retinoblastoma Protein | 3 | 2006 | 66 | 0.100 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2005 | 878 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.100 |
Why?
|
Nephrectomy | 4 | 2019 | 294 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2004 | 292 | 0.100 |
Why?
|
Cross-Over Studies | 2 | 2009 | 399 | 0.100 |
Why?
|
ErbB Receptors | 3 | 2020 | 485 | 0.100 |
Why?
|
Laser Therapy | 1 | 2013 | 142 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2015 | 533 | 0.100 |
Why?
|
Purine-Nucleoside Phosphorylase | 3 | 1996 | 23 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2011 | 46 | 0.100 |
Why?
|
Frail Elderly | 2 | 2011 | 71 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 53 | 0.100 |
Why?
|
Protein Interaction Mapping | 1 | 2011 | 82 | 0.100 |
Why?
|
Estramustine | 1 | 2010 | 1 | 0.100 |
Why?
|
Risk Factors | 8 | 2016 | 5417 | 0.100 |
Why?
|
Interferons | 2 | 2006 | 133 | 0.100 |
Why?
|
Snake Venoms | 1 | 2010 | 10 | 0.100 |
Why?
|
Disease Models, Animal | 3 | 2012 | 2232 | 0.100 |
Why?
|
Hemofiltration | 1 | 2010 | 11 | 0.100 |
Why?
|
Health Resources | 1 | 2011 | 76 | 0.100 |
Why?
|
Radioisotopes | 2 | 2023 | 45 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2010 | 104 | 0.090 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 1999 | 110 | 0.090 |
Why?
|
Thiazoles | 1 | 2011 | 131 | 0.090 |
Why?
|
Pharmacy and Therapeutics Committee | 1 | 2010 | 5 | 0.090 |
Why?
|
Compassionate Use Trials | 1 | 2010 | 8 | 0.090 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2010 | 45 | 0.090 |
Why?
|
Hemoglobinopathies | 1 | 2010 | 10 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2012 | 188 | 0.090 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2007 | 126 | 0.090 |
Why?
|
Activities of Daily Living | 2 | 2008 | 204 | 0.090 |
Why?
|
Young Adult | 6 | 2018 | 5976 | 0.090 |
Why?
|
Ketoconazole | 2 | 2013 | 25 | 0.090 |
Why?
|
Immediate-Early Proteins | 1 | 2011 | 164 | 0.090 |
Why?
|
Drugs, Investigational | 1 | 2010 | 37 | 0.090 |
Why?
|
Hydroxamic Acids | 1 | 2009 | 49 | 0.090 |
Why?
|
North America | 1 | 2010 | 180 | 0.090 |
Why?
|
MAP Kinase Kinase 7 | 2 | 2007 | 21 | 0.090 |
Why?
|
Kidney Medulla | 1 | 2010 | 80 | 0.090 |
Why?
|
Reference Values | 2 | 2009 | 674 | 0.090 |
Why?
|
Monte Carlo Method | 2 | 2013 | 185 | 0.090 |
Why?
|
Self Report | 1 | 2011 | 288 | 0.090 |
Why?
|
Nitriles | 3 | 2022 | 149 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2012 | 351 | 0.090 |
Why?
|
Administration, Cutaneous | 1 | 2009 | 58 | 0.090 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 83 | 0.090 |
Why?
|
Muscle Strength | 1 | 2009 | 31 | 0.090 |
Why?
|
HLA-A2 Antigen | 1 | 2009 | 31 | 0.090 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 2426 | 0.090 |
Why?
|
Phosphorylation | 4 | 2009 | 1106 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 2008 | 24 | 0.080 |
Why?
|
Tuberculosis, Urogenital | 1 | 1988 | 3 | 0.080 |
Why?
|
Registries | 2 | 2023 | 702 | 0.080 |
Why?
|
Prostate | 1 | 2012 | 378 | 0.080 |
Why?
|
Lactoferrin | 1 | 2008 | 11 | 0.080 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 879 | 0.080 |
Why?
|
Interpersonal Relations | 1 | 2009 | 170 | 0.080 |
Why?
|
Antitubercular Agents | 1 | 1988 | 52 | 0.080 |
Why?
|
Interleukin-12 | 1 | 2009 | 108 | 0.080 |
Why?
|
Neoplasm Grading | 3 | 2015 | 357 | 0.080 |
Why?
|
Epitopes | 1 | 2009 | 255 | 0.080 |
Why?
|
Neuropsychological Tests | 1 | 2010 | 502 | 0.080 |
Why?
|
Computational Biology | 1 | 2011 | 528 | 0.080 |
Why?
|
Physical Fitness | 1 | 2008 | 51 | 0.080 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2008 | 35 | 0.080 |
Why?
|
Injections, Intra-Arterial | 1 | 2007 | 33 | 0.080 |
Why?
|
Mitoxantrone | 1 | 2008 | 68 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 83 | 0.080 |
Why?
|
Anemia, Sickle Cell | 1 | 2010 | 131 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2007 | 1076 | 0.080 |
Why?
|
Area Under Curve | 1 | 2008 | 334 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 508 | 0.080 |
Why?
|
Protein Kinases | 1 | 2009 | 209 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2013 | 999 | 0.080 |
Why?
|
Bortezomib | 2 | 2006 | 76 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 2357 | 0.080 |
Why?
|
Liver | 2 | 2021 | 1230 | 0.080 |
Why?
|
Incidence | 2 | 2004 | 1577 | 0.080 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 15 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 275 | 0.080 |
Why?
|
Drug Evaluation | 1 | 2007 | 141 | 0.080 |
Why?
|
Adolescent | 5 | 2013 | 8981 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2021 | 2903 | 0.070 |
Why?
|
Oncogenes | 1 | 2007 | 88 | 0.070 |
Why?
|
Microarray Analysis | 1 | 2006 | 96 | 0.070 |
Why?
|
Logistic Models | 1 | 2010 | 1186 | 0.070 |
Why?
|
MicroRNAs | 1 | 2011 | 534 | 0.070 |
Why?
|
Receptors, Glucocorticoid | 2 | 2022 | 120 | 0.070 |
Why?
|
Case-Control Studies | 4 | 2016 | 1805 | 0.070 |
Why?
|
Bryostatins | 1 | 2006 | 15 | 0.070 |
Why?
|
Vulnerable Populations | 1 | 2007 | 76 | 0.070 |
Why?
|
Matrix Metalloproteinase Inhibitors | 1 | 2006 | 14 | 0.070 |
Why?
|
Disability Evaluation | 1 | 2007 | 136 | 0.070 |
Why?
|
Membrane Glycoproteins | 1 | 2008 | 428 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.070 |
Why?
|
Swainsonine | 1 | 2005 | 1 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 1565 | 0.070 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2006 | 67 | 0.070 |
Why?
|
Flutamide | 1 | 2005 | 4 | 0.070 |
Why?
|
Osteoporosis | 1 | 2007 | 121 | 0.070 |
Why?
|
Carboplatin | 2 | 2009 | 286 | 0.070 |
Why?
|
Imatinib Mesylate | 1 | 2006 | 126 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 1036 | 0.070 |
Why?
|
Dexamethasone | 2 | 2004 | 326 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2007 | 166 | 0.070 |
Why?
|
Placenta Growth Factor | 2 | 2021 | 70 | 0.070 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 113 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 2601 | 0.070 |
Why?
|
Injections, Intravenous | 2 | 2004 | 244 | 0.070 |
Why?
|
Transplantation Conditioning | 2 | 2005 | 373 | 0.070 |
Why?
|
Oligonucleotides, Antisense | 1 | 2005 | 69 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2006 | 183 | 0.060 |
Why?
|
Immunotherapy, Adoptive | 1 | 2006 | 170 | 0.060 |
Why?
|
Receptor Cross-Talk | 1 | 2004 | 33 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 11 | 0.060 |
Why?
|
Piperazines | 1 | 2006 | 272 | 0.060 |
Why?
|
B7-H1 Antigen | 2 | 2016 | 250 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 332 | 0.060 |
Why?
|
Hypertension | 2 | 2010 | 1141 | 0.060 |
Why?
|
Multienzyme Complexes | 1 | 2004 | 64 | 0.060 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2000 | 43 | 0.060 |
Why?
|
Scandium | 1 | 2023 | 5 | 0.060 |
Why?
|
Anorexia | 2 | 2001 | 30 | 0.060 |
Why?
|
Postoperative Period | 1 | 2004 | 303 | 0.060 |
Why?
|
Cysteine Endopeptidases | 1 | 2004 | 87 | 0.060 |
Why?
|
Fibroblast Growth Factors | 1 | 2004 | 80 | 0.060 |
Why?
|
Arteries | 1 | 2004 | 176 | 0.060 |
Why?
|
Camptothecin | 1 | 2004 | 189 | 0.060 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2004 | 100 | 0.060 |
Why?
|
Lymphocytes | 3 | 2016 | 464 | 0.060 |
Why?
|
Cell Line | 3 | 1999 | 2468 | 0.060 |
Why?
|
Paresthesia | 1 | 2003 | 16 | 0.060 |
Why?
|
Pharynx | 1 | 2003 | 45 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2003 | 127 | 0.060 |
Why?
|
Larynx | 1 | 2003 | 38 | 0.060 |
Why?
|
Withholding Treatment | 1 | 2003 | 112 | 0.060 |
Why?
|
Glutaminase | 1 | 2022 | 12 | 0.060 |
Why?
|
Iodine Radioisotopes | 1 | 2023 | 134 | 0.060 |
Why?
|
Life Tables | 1 | 2002 | 48 | 0.050 |
Why?
|
Integrin alphaXbeta2 | 1 | 2002 | 3 | 0.050 |
Why?
|
Glutamates | 1 | 2022 | 89 | 0.050 |
Why?
|
Genes, Neurofibromatosis 2 | 1 | 2022 | 10 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2005 | 435 | 0.050 |
Why?
|
Androgen Receptor Antagonists | 1 | 2022 | 18 | 0.050 |
Why?
|
Benzoxazoles | 1 | 2022 | 4 | 0.050 |
Why?
|
Mifepristone | 1 | 2022 | 33 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2014 | 70 | 0.050 |
Why?
|
Glutamine | 1 | 2022 | 76 | 0.050 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2002 | 118 | 0.050 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 41 | 0.050 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 29 | 0.050 |
Why?
|
Odds Ratio | 2 | 2015 | 678 | 0.050 |
Why?
|
Phenotype | 3 | 2016 | 2378 | 0.050 |
Why?
|
Trastuzumab | 1 | 2002 | 68 | 0.050 |
Why?
|
Radiotherapy | 2 | 2006 | 328 | 0.050 |
Why?
|
Immunophenotyping | 1 | 2002 | 211 | 0.050 |
Why?
|
DNA, Neoplasm | 3 | 2003 | 265 | 0.050 |
Why?
|
Neutropenia | 2 | 2018 | 215 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2008 | 744 | 0.050 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 16 | 0.050 |
Why?
|
Aneuploidy | 1 | 2001 | 55 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2001 | 47 | 0.050 |
Why?
|
Thionucleotides | 1 | 2001 | 56 | 0.050 |
Why?
|
Renal Insufficiency | 1 | 2002 | 114 | 0.050 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 449 | 0.050 |
Why?
|
Lymphokines | 1 | 2021 | 76 | 0.050 |
Why?
|
Acute Disease | 1 | 2003 | 826 | 0.050 |
Why?
|
Genes, p53 | 1 | 2001 | 109 | 0.050 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2000 | 7 | 0.050 |
Why?
|
Pyrazoles | 1 | 2022 | 153 | 0.050 |
Why?
|
beta-Galactosidase | 1 | 2000 | 71 | 0.050 |
Why?
|
Remission Induction | 2 | 2000 | 722 | 0.050 |
Why?
|
Biopsy | 2 | 2016 | 1163 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2000 | 30 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2016 | 369 | 0.050 |
Why?
|
Watchful Waiting | 1 | 2021 | 60 | 0.050 |
Why?
|
Ribonucleases | 1 | 2001 | 92 | 0.050 |
Why?
|
Cyclins | 1 | 2000 | 82 | 0.050 |
Why?
|
Drug Interactions | 1 | 2021 | 248 | 0.050 |
Why?
|
Cell Line, Transformed | 1 | 2000 | 154 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 74 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 364 | 0.050 |
Why?
|
Asthenia | 1 | 2000 | 4 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2020 | 50 | 0.050 |
Why?
|
Endothelium | 1 | 2000 | 59 | 0.050 |
Why?
|
Steroids | 1 | 2021 | 177 | 0.050 |
Why?
|
Genes, Reporter | 1 | 2000 | 268 | 0.050 |
Why?
|
Cyclohexanes | 1 | 1999 | 9 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2003 | 927 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2004 | 556 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2004 | 724 | 0.040 |
Why?
|
Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
Fever | 1 | 2000 | 125 | 0.040 |
Why?
|
Heart Arrest | 1 | 2002 | 265 | 0.040 |
Why?
|
Rats | 4 | 2005 | 3990 | 0.040 |
Why?
|
Vincristine | 1 | 2019 | 111 | 0.040 |
Why?
|
Risk | 2 | 2012 | 674 | 0.040 |
Why?
|
Decision Making | 1 | 2004 | 642 | 0.040 |
Why?
|
Abiraterone Acetate | 1 | 2018 | 11 | 0.040 |
Why?
|
von Hippel-Lindau Disease | 1 | 1998 | 17 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 1998 | 53 | 0.040 |
Why?
|
Dendritic Cells | 1 | 2002 | 425 | 0.040 |
Why?
|
Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
Nontherapeutic Human Experimentation | 1 | 1998 | 20 | 0.040 |
Why?
|
Bradycardia | 1 | 2018 | 39 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 1075 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2014 | 679 | 0.040 |
Why?
|
Nephroureterectomy | 1 | 2018 | 2 | 0.040 |
Why?
|
Cell Death | 1 | 1999 | 256 | 0.040 |
Why?
|
Etoposide | 1 | 2019 | 196 | 0.040 |
Why?
|
Sex Distribution | 1 | 1998 | 173 | 0.040 |
Why?
|
Singapore | 1 | 2018 | 16 | 0.040 |
Why?
|
Age Distribution | 1 | 1998 | 204 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2000 | 378 | 0.040 |
Why?
|
Gallium | 1 | 1998 | 4 | 0.040 |
Why?
|
bcl-X Protein | 1 | 1998 | 52 | 0.040 |
Why?
|
Blotting, Southern | 2 | 1998 | 129 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2019 | 193 | 0.040 |
Why?
|
Ifosfamide | 1 | 1998 | 49 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2018 | 51 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2019 | 299 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2001 | 503 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2000 | 371 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2005 | 689 | 0.040 |
Why?
|
Retinoblastoma | 1 | 1998 | 28 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 25 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2019 | 265 | 0.040 |
Why?
|
Erlotinib Hydrochloride | 2 | 2008 | 90 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2018 | 68 | 0.040 |
Why?
|
Research Subjects | 1 | 1998 | 73 | 0.040 |
Why?
|
Restriction Mapping | 2 | 1995 | 157 | 0.040 |
Why?
|
Fasting | 1 | 2018 | 161 | 0.040 |
Why?
|
Research | 1 | 2019 | 253 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 72 | 0.040 |
Why?
|
Oxidative Stress | 1 | 2000 | 447 | 0.040 |
Why?
|
Cell Survival | 1 | 2000 | 969 | 0.040 |
Why?
|
Lymphatic Vessels | 1 | 2018 | 68 | 0.040 |
Why?
|
Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
Tosyl Compounds | 2 | 2008 | 15 | 0.040 |
Why?
|
Beta Particles | 1 | 2016 | 5 | 0.040 |
Why?
|
MAP Kinase Kinase 6 | 2 | 2007 | 12 | 0.040 |
Why?
|
Thrombosis | 1 | 2000 | 296 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2000 | 645 | 0.040 |
Why?
|
Patient Preference | 1 | 2017 | 105 | 0.040 |
Why?
|
Prevalence | 1 | 2021 | 1239 | 0.040 |
Why?
|
Health Personnel | 1 | 2019 | 202 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2016 | 7 | 0.040 |
Why?
|
Papillomavirus E7 Proteins | 1 | 1996 | 31 | 0.040 |
Why?
|
Infant | 1 | 2023 | 3046 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 384 | 0.040 |
Why?
|
Chemokine CXCL10 | 1 | 2016 | 17 | 0.040 |
Why?
|
Osteoblasts | 1 | 2016 | 95 | 0.040 |
Why?
|
Social Perception | 1 | 2017 | 95 | 0.040 |
Why?
|
Immunomodulation | 1 | 2016 | 55 | 0.030 |
Why?
|
Patient Participation | 1 | 1998 | 216 | 0.030 |
Why?
|
CD27 Ligand | 1 | 2015 | 1 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 24 | 0.030 |
Why?
|
Urinary Tract | 1 | 1996 | 34 | 0.030 |
Why?
|
Receptors, IgE | 1 | 1995 | 7 | 0.030 |
Why?
|
PPAR gamma | 1 | 2016 | 66 | 0.030 |
Why?
|
Gossypol | 1 | 2015 | 6 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
Pharmacogenomic Variants | 1 | 2016 | 41 | 0.030 |
Why?
|
Ethics, Medical | 1 | 1998 | 306 | 0.030 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1995 | 37 | 0.030 |
Why?
|
Informed Consent | 1 | 1998 | 266 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 69 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2018 | 352 | 0.030 |
Why?
|
Attitude to Health | 1 | 2017 | 220 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2016 | 180 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2008 | 293 | 0.030 |
Why?
|
Solubility | 1 | 1995 | 177 | 0.030 |
Why?
|
Communication | 1 | 2019 | 441 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 123 | 0.030 |
Why?
|
Genes, Retinoblastoma | 1 | 1995 | 22 | 0.030 |
Why?
|
Proteins | 1 | 2000 | 777 | 0.030 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2016 | 159 | 0.030 |
Why?
|
Laser Capture Microdissection | 1 | 2014 | 20 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 376 | 0.030 |
Why?
|
beta Catenin | 1 | 2016 | 251 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 1673 | 0.030 |
Why?
|
Chromosome Banding | 1 | 1994 | 74 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1995 | 646 | 0.030 |
Why?
|
Consensus | 1 | 2016 | 335 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 814 | 0.030 |
Why?
|
Genetic Testing | 1 | 2018 | 535 | 0.030 |
Why?
|
Cells, Cultured | 2 | 1996 | 2818 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2013 | 68 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 34 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2013 | 79 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 296 | 0.030 |
Why?
|
Genes, ras | 1 | 2013 | 96 | 0.030 |
Why?
|
Multigene Family | 1 | 1994 | 202 | 0.030 |
Why?
|
Telomere | 1 | 1994 | 108 | 0.030 |
Why?
|
Growth Substances | 1 | 1993 | 80 | 0.030 |
Why?
|
Biopsy, Needle | 2 | 2004 | 235 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2013 | 127 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2013 | 190 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2005 | 192 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 526 | 0.030 |
Why?
|
Antifungal Agents | 1 | 2013 | 117 | 0.030 |
Why?
|
Blotting, Western | 2 | 2008 | 782 | 0.030 |
Why?
|
Mice, SCID | 2 | 2005 | 252 | 0.030 |
Why?
|
Drug Therapy | 1 | 2012 | 70 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 307 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2005 | 692 | 0.030 |
Why?
|
United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
Graft vs Host Disease | 2 | 2006 | 365 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 1993 | 286 | 0.030 |
Why?
|
Calgranulin B | 1 | 2011 | 16 | 0.030 |
Why?
|
Leucovorin | 1 | 1992 | 218 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2011 | 14 | 0.030 |
Why?
|
Selection Bias | 1 | 2011 | 37 | 0.030 |
Why?
|
Patient Care Team | 1 | 1994 | 280 | 0.030 |
Why?
|
Dasatinib | 1 | 2011 | 37 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 162 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2011 | 57 | 0.020 |
Why?
|
Transfection | 2 | 2005 | 896 | 0.020 |
Why?
|
Transplantation, Homologous | 2 | 2005 | 996 | 0.020 |
Why?
|
Life Expectancy | 1 | 2011 | 86 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 124 | 0.020 |
Why?
|
Xylenes | 1 | 2010 | 3 | 0.020 |
Why?
|
Dimethylpolysiloxanes | 1 | 2010 | 15 | 0.020 |
Why?
|
Bone Marrow | 2 | 2003 | 435 | 0.020 |
Why?
|
Membranes, Artificial | 1 | 2010 | 40 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2011 | 227 | 0.020 |
Why?
|
Iohexol | 1 | 2010 | 26 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2010 | 84 | 0.020 |
Why?
|
Ultrasonography | 1 | 2013 | 695 | 0.020 |
Why?
|
Base Sequence | 3 | 2003 | 2330 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2003 | 1981 | 0.020 |
Why?
|
Mice, Nude | 2 | 2005 | 790 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 227 | 0.020 |
Why?
|
Platinum Compounds | 1 | 2009 | 31 | 0.020 |
Why?
|
Canada | 1 | 2010 | 204 | 0.020 |
Why?
|
Retreatment | 1 | 2009 | 107 | 0.020 |
Why?
|
Transcription, Genetic | 2 | 2005 | 1135 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 3030 | 0.020 |
Why?
|
Polymers | 1 | 2010 | 202 | 0.020 |
Why?
|
Lymphopenia | 1 | 2009 | 28 | 0.020 |
Why?
|
Mucositis | 1 | 2009 | 17 | 0.020 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2008 | 31 | 0.020 |
Why?
|
Mucin-1 | 1 | 2008 | 44 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 24 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 429 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2008 | 26 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2009 | 69 | 0.020 |
Why?
|
Paxillin | 1 | 2008 | 59 | 0.020 |
Why?
|
Southwestern United States | 1 | 2008 | 8 | 0.020 |
Why?
|
Goserelin | 1 | 2008 | 6 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2008 | 38 | 0.020 |
Why?
|
Artifacts | 1 | 2010 | 244 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2009 | 468 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2007 | 19 | 0.020 |
Why?
|
NF-kappa B | 1 | 2011 | 444 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2009 | 173 | 0.020 |
Why?
|
MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 175 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2009 | 254 | 0.020 |
Why?
|
Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 146 | 0.020 |
Why?
|
Pentoxifylline | 2 | 1998 | 9 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2007 | 61 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2009 | 912 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 1920 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2009 | 302 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 2271 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2009 | 303 | 0.020 |
Why?
|
Graft vs Tumor Effect | 1 | 2006 | 25 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 91 | 0.020 |
Why?
|
Mannosidases | 1 | 2005 | 2 | 0.020 |
Why?
|
Phytohemagglutinins | 1 | 2005 | 22 | 0.020 |
Why?
|
Bone Density | 1 | 2007 | 209 | 0.020 |
Why?
|
Weight Loss | 1 | 2007 | 229 | 0.020 |
Why?
|
Epithelium | 2 | 1998 | 319 | 0.020 |
Why?
|
Motor Activity | 1 | 2007 | 327 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 28 | 0.020 |
Why?
|
Propionates | 1 | 2005 | 34 | 0.020 |
Why?
|
Histocompatibility | 1 | 2005 | 71 | 0.020 |
Why?
|
Siblings | 1 | 2005 | 111 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 78 | 0.020 |
Why?
|
Obesity | 1 | 2011 | 963 | 0.020 |
Why?
|
Biological Availability | 1 | 2004 | 92 | 0.020 |
Why?
|
Leukemia | 1 | 2006 | 320 | 0.010 |
Why?
|
Blood Pressure | 1 | 2009 | 1143 | 0.010 |
Why?
|
Gene Library | 1 | 2004 | 130 | 0.010 |
Why?
|
Cause of Death | 1 | 2005 | 277 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2004 | 148 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2007 | 1540 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 68 | 0.010 |
Why?
|
Anemia | 1 | 2004 | 128 | 0.010 |
Why?
|
Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2004 | 267 | 0.010 |
Why?
|
Societies, Medical | 1 | 2006 | 572 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2004 | 298 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2003 | 222 | 0.010 |
Why?
|
Cytokines | 1 | 2006 | 776 | 0.010 |
Why?
|
Recurrence | 1 | 2005 | 1139 | 0.010 |
Why?
|
Transplantation Immunology | 1 | 2002 | 84 | 0.010 |
Why?
|
Illinois | 1 | 2003 | 462 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2002 | 62 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2007 | 1621 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 926 | 0.010 |
Why?
|
Glucose | 1 | 2004 | 638 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 2001 | 85 | 0.010 |
Why?
|
Complement System Proteins | 1 | 2001 | 81 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 2001 | 46 | 0.010 |
Why?
|
Glucuronates | 1 | 2000 | 22 | 0.010 |
Why?
|
Blood Coagulation | 1 | 2001 | 91 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 3092 | 0.010 |
Why?
|
Lactones | 1 | 2000 | 28 | 0.010 |
Why?
|
Macrolides | 1 | 2000 | 31 | 0.010 |
Why?
|
Immunoblotting | 1 | 2000 | 268 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 977 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1999 | 393 | 0.010 |
Why?
|
Biotransformation | 1 | 1998 | 50 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2003 | 509 | 0.010 |
Why?
|
Antibodies | 1 | 2000 | 350 | 0.010 |
Why?
|
Therapeutic Irrigation | 1 | 1997 | 60 | 0.010 |
Why?
|
Cell Count | 1 | 1998 | 195 | 0.010 |
Why?
|
Comprehension | 1 | 1998 | 79 | 0.010 |
Why?
|
Personal Autonomy | 1 | 1998 | 112 | 0.010 |
Why?
|
Disclosure | 1 | 1998 | 108 | 0.010 |
Why?
|
Light | 1 | 1998 | 289 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 1998 | 152 | 0.010 |
Why?
|
Tissue Donors | 1 | 2000 | 463 | 0.010 |
Why?
|
Cystoscopy | 1 | 1996 | 35 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1996 | 39 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 1996 | 167 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1995 | 135 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 416 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 543 | 0.010 |
Why?
|
Lung | 1 | 1999 | 1170 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 2062 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 1995 | 819 | 0.010 |
Why?
|
Epithelial Cells | 1 | 1995 | 669 | 0.010 |
Why?
|
Gene Expression | 1 | 1995 | 1284 | 0.010 |
Why?
|